Cargando…

Dietary supplements quality analysis tools from the United States Pharmacopeia

The United States Food and Drug Administration (FDA) issued the dietary supplement (DS) current good manufacturing practice (GMP) regulations in compliance with the mandate from the Dietary Supplements Health and Education Act (DSHEA), with the intention of protecting public health by ensuring the q...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarma, Nandakumara, Giancaspro, Gabriel, Venema, Jaap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072169/
https://www.ncbi.nlm.nih.gov/pubmed/26857794
http://dx.doi.org/10.1002/dta.1940
_version_ 1782461360061284352
author Sarma, Nandakumara
Giancaspro, Gabriel
Venema, Jaap
author_facet Sarma, Nandakumara
Giancaspro, Gabriel
Venema, Jaap
author_sort Sarma, Nandakumara
collection PubMed
description The United States Food and Drug Administration (FDA) issued the dietary supplement (DS) current good manufacturing practice (GMP) regulations in compliance with the mandate from the Dietary Supplements Health and Education Act (DSHEA), with the intention of protecting public health by ensuring the quality of DS. The GMP regulations require manufacturers to establish their own quality specifications for identity, purity, strength, composition, and absence of contaminants. Numerous FDA‐conducted GMP inspections found that the private specifications set by these manufacturers are often insufficient to ensure adequate quality of dietary ingredients and DS. Wider use of the public standards developed by the United States Pharmacopeial Convention (USP), in conjunction with GMP compliance, can help ensure quality and consistency of DS as they do for medicines. Public health protection could be enhanced by strengthening the GMP provisions to require conformance with relevant United States Pharmacopeia–National Formulary (USP–NF) standards, or in the absence of USP standards, other public compendial standards. Another serious concern is the presence of synthetic drugs and drug analogues in products marketed as DS. Use of the new USP General Chapter Adulteration of Dietary Supplements with Drugs and Drug Analogs <2251> may reduce the exposure of consumers to dangerous drugs disguised as DS. © 2016 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
format Online
Article
Text
id pubmed-5072169
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50721692016-11-02 Dietary supplements quality analysis tools from the United States Pharmacopeia Sarma, Nandakumara Giancaspro, Gabriel Venema, Jaap Drug Test Anal Perspectives The United States Food and Drug Administration (FDA) issued the dietary supplement (DS) current good manufacturing practice (GMP) regulations in compliance with the mandate from the Dietary Supplements Health and Education Act (DSHEA), with the intention of protecting public health by ensuring the quality of DS. The GMP regulations require manufacturers to establish their own quality specifications for identity, purity, strength, composition, and absence of contaminants. Numerous FDA‐conducted GMP inspections found that the private specifications set by these manufacturers are often insufficient to ensure adequate quality of dietary ingredients and DS. Wider use of the public standards developed by the United States Pharmacopeial Convention (USP), in conjunction with GMP compliance, can help ensure quality and consistency of DS as they do for medicines. Public health protection could be enhanced by strengthening the GMP provisions to require conformance with relevant United States Pharmacopeia–National Formulary (USP–NF) standards, or in the absence of USP standards, other public compendial standards. Another serious concern is the presence of synthetic drugs and drug analogues in products marketed as DS. Use of the new USP General Chapter Adulteration of Dietary Supplements with Drugs and Drug Analogs <2251> may reduce the exposure of consumers to dangerous drugs disguised as DS. © 2016 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. John Wiley and Sons Inc. 2016-02-09 2016 /pmc/articles/PMC5072169/ /pubmed/26857794 http://dx.doi.org/10.1002/dta.1940 Text en © 2016 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Perspectives
Sarma, Nandakumara
Giancaspro, Gabriel
Venema, Jaap
Dietary supplements quality analysis tools from the United States Pharmacopeia
title Dietary supplements quality analysis tools from the United States Pharmacopeia
title_full Dietary supplements quality analysis tools from the United States Pharmacopeia
title_fullStr Dietary supplements quality analysis tools from the United States Pharmacopeia
title_full_unstemmed Dietary supplements quality analysis tools from the United States Pharmacopeia
title_short Dietary supplements quality analysis tools from the United States Pharmacopeia
title_sort dietary supplements quality analysis tools from the united states pharmacopeia
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072169/
https://www.ncbi.nlm.nih.gov/pubmed/26857794
http://dx.doi.org/10.1002/dta.1940
work_keys_str_mv AT sarmanandakumara dietarysupplementsqualityanalysistoolsfromtheunitedstatespharmacopeia
AT giancasprogabriel dietarysupplementsqualityanalysistoolsfromtheunitedstatespharmacopeia
AT venemajaap dietarysupplementsqualityanalysistoolsfromtheunitedstatespharmacopeia